Summit Therapeutics PLC (SMMT) experienced a sharp intraday decline, with its stock price plummeting 7.41% on Monday.

This sell-off occurred despite the company recently announcing positive Phase III trial results for its experimental lung cancer drug, ivonescimab, which demonstrated a significant reduction in the risk of death and improved overall survival compared to a competitor's treatment.

Investor sentiment appeared mixed, with analysts highlighting that the clinical study was conducted solely in China, raising questions about the drug's efficacy and applicability to Western patient populations. Furthermore, some market observers expressed skepticism about ivonescimab's immediate competitive threat to established treatments like Merck's Keytruda, tempering initial optimism and contributing to the downward pressure on the stock.